PDSB PDS Biotechnology Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: PDSB

Price (delayed)

$5.15

Market cap

$160.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.71

Enterprise value

$129.56M

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively ...

Highlights
PDS Biotechnology's net income has plunged by 83% YoY and by 7% from the previous quarter
PDS Biotechnology's EPS has shrunk by 69% YoY and by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.pdsbiotech.com
Peers: OMGA

Key stats

What are the main financial stats of PDSB
Market
Shares outstanding
31.11M
Market cap
$160.2M
Enterprise value
$129.56M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.49
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$51.46M
EBITDA
-$51.2M
Free cash flow
-$32.71M
Per share
EPS
-$1.71
Free cash flow per share
-$1.06
Book value per share
$0.79
Revenue per share
$0
TBVPS
$1.85
Balance sheet
Total assets
$57.19M
Total liabilities
$32.7M
Debt
$23.6M
Equity
$24.48M
Working capital
$47.68M
Liquidity
Debt to equity
0.96
Current ratio
6.21
Quick ratio
5.93
Net debt/EBITDA
0.6
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-76.8%
Return on equity
-144.2%
Return on invested capital
-272.3%
Return on capital employed
-107.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PDSB stock price

How has the PDS Biotechnology stock price performed over time
Intraday
-3.38%
1 week
-16.4%
1 month
28.11%
1 year
-35.79%
YTD
-60.98%
QTD
1.98%

Financial performance

How have PDS Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.46M
Net income
-$51.18M
Gross margin
N/A
Net margin
N/A
PDS Biotechnology's net income has plunged by 83% YoY and by 7% from the previous quarter
The operating income has plunged by 76% YoY and by 7% from the previous quarter

Growth

What is PDS Biotechnology's growth rate over time

Valuation

What is PDS Biotechnology stock price valuation
P/E
N/A
P/B
6.49
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PDS Biotechnology's EPS has shrunk by 69% YoY and by 6% QoQ
The P/B is 117% higher than the 5-year quarterly average of 3.1 and 10% higher than the last 4 quarters average of 6.1
The equity has contracted by 48% YoY and by 25% from the previous quarter

Efficiency

How efficient is PDS Biotechnology business performance
PDSB's ROE has shrunk by 180% YoY and by 24% QoQ
The ROA has shrunk by 77% YoY and by 14% QoQ
PDS Biotechnology's ROIC has soared by 60% YoY but it has decreased by 13% from the previous quarter

Dividends

What is PDSB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PDSB.

Financial health

How did PDS Biotechnology financials performed over time
PDS Biotechnology's total assets is 75% more than its total liabilities
The quick ratio has plunged by 60% YoY and by 23% from the previous quarter
PDSB's current ratio has dropped by 60% year-on-year and by 22% since the previous quarter
PDS Biotechnology's debt is 3.6% lower than its equity
The debt to equity has soared by 92% year-on-year and by 33% since the previous quarter
The equity has contracted by 48% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.